Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839220 | 0.85 | ENPP2 (0.64) | ENPP2CXCR3HDAC6POLBHDAC1 | |
| SCHEMBL838967 | 0.78 | ENPP2 (0.47) | ENPP2HDAC6POLBHDAC1HDAC2 | |
| SCHEMBL838966 | 0.78 | ENPP2 (0.47) | ENPP2HDAC6POLBHDAC1HDAC2 | |
| SCHEMBL838675 | 0.74 | ENPP2 (0.43) | ENPP2HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL840164 | 0.74 | HDAC6 (0.50) | ENPP2HDAC6POLBHDAC1HDAC2 | |
| SCHEMBL839110 | 0.73 | ENPP2 (0.56) | ENPP2HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL839218 | 0.72 | HDAC6 (0.50) | ENPP2CXCR3HDAC6HDAC1HDAC2 | |
| SCHEMBL840710 | 0.71 | HDAC6 (0.45) | ENPP2HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL839034 | 0.71 | ENPP2 (0.60) | ENPP2HDAC6HDAC1HDAC2HDAC8 | |
| SCHEMBL839274 | 0.70 | HDAC6 (0.54) | ENPP2CXCR3HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| EP-2373639-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063666-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | ENPP2 1230/4885CXCR3 111/4885HDAC6 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.